Jia Zhou

Prof

University of Texas Medical Branch at Galveston

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jia Zhou is a Professor at the University of Texas Medical Branch at Galveston, USA. His research areas include cancer biomarkers, immunotherapy, neurotherapeutics, and innovative drug development strategies. He has contributed significantly to the understanding of CDK9 inhibitors, precision cancer therapies, and the potential of psychedelics in drug development, as reflected in his recent publications.

Articles (23)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (5)

Dinler Antunes

Assistant Professor of Computational Biology

University of Houston

UNITED STATES

View details

Paul Wadsworth

University of Texas Medical Branch at Galveston

UNITED STATES

View details

Fernanda Laezza

University of Texas Medical Branch

UNITED STATES

View details

Hongmin Li

R. Ken and Donna Coit Endowed Chair Professor

University of Arizona

UNITED STATES

View details

Zhipin Liang

Assistant Professor-Research

LSUHSC

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jia Zhou

Research Interests

Explore related searches

Contact this professor

About

Articles (23)

Exploring CISD1 as a multifaceted biomarker in cancer: Implications for diagnosis, prognosis, and immunotherapeutic response

FGF14 Peptide Derivative Differentially Regulates Nav1.2 and Na<sub>v</sub>1.6 Function

YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma

Old Dog, New Tricks: Ibogaine and Its Analogs as Potential Neurotherapeutics

NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders

Small-Molecule Strategies against Human Adenoviruses: Progress, Challenges, and Future Perspectives

RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a Phase III Clinical Candidate Daraxonrasib (RMC-6236)

RIPTACs for Precision Cancer Therapy: A Novel Modality with the Inspiration of HLD-0915 as the First Candidate in Clinical Trials

Salicylamide derivative JMX0312 protects immunosuppressed Syrian hamsters against adenovirus lethal challenge

Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond

An updated patent review of BRD4 degraders

Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists

Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics

Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target

Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)

Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018–2022)

Therapeutic potential of salicylamide derivatives for combating viral infections

Novel approaches to targeted protein degradation technologies in drug discovery

Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics

Retraction of “Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists”

Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer

Antiviral Agents against Flavivirus Protease: Prospect and Future Direction

Pharmacologically Targeting the Fibroblast Growth Factor 14 Interaction Site on the Voltage-Gated Na+ Channel 1.6 Enables Isoform-Selective Modulation

Collaborators (5)

Dinler Antunes

Paul Wadsworth

Fernanda Laezza

Hongmin Li

Zhipin Liang

Make your next move.